Table 2. Case studies on the use of various ALK inhibitors in individuals with advanced/metastatic IMT.
Reference | Targeted therapy* | ALK status | Other treatment | Response to treatment | Patient information (age, sex, primary tumor site) |
---|---|---|---|---|---|
[189] | Crizotinib 500 mg/day | RANBP2-ALK rearrangement | Surgery | PR | 22; male; pelvis with peritoneal dissemination |
[190] | Crizotinib | ALK rearrangement | – | CR | 45; female; liver; metastatic |
[191] | Crizotinib 250 mg/2 times a day | RANBP2-ALK rearrangement | Surgery, chemotherapy with doxorubicin | CR | 22; male; pelvis |
[192] | Crizotinib | CLTC-ALK rearrangement | – | SD | 24; male; omentum, liver, colon |
[193] | Crizotinib 250 mg on alternate days | DCTN1-ALK rearrangement | Pazopanib | PR | 50; female; uterine |
[194] | Crizotinib 200 mg/twice daily | – | – | CR | 7; female; right eye |
[195] | Crizotinib 250 mg/2 times a day | EML4-ALK rearrangement | Non-steroidal anti-inflammatory drugs, steroids, vinblastine, combination chemotherapy with alternate VAC/VA, and vinorelbine and methotrexate, palliative radiotherapy | CR | 16; female; right arm |
[196] | Crizotinib | RANBP2-ALK rearrangement | 6 cycles of chemotherapy in 4 was gemcitabine with docetaxel | PR | 15; female; ovary; recurrence |
[82] | Crizotinib 250 mg/2 times a day | NUMA1-ALK rearrangement | Nivolumab at 3 mg/kg intravenously every 2 weeks | CR | 21; female; left arm; metastatic |
[106] | Crizotinib 250 mg/2 times a day | LRRFIP1-ALK rearrangement | – | PR | 15; male; hip |
[197] | Crizotinib 500 mg daily | ALK rearrangement | Surgery | CR | 37; female; right adrenal gland and inferior vena cava; metastatic |
[198] | Crizotinib | ALK wt | – | PR | 31; male; lung; metastatic |
[199] | Crizotinib 250 mg/2 times a day | IGFBP5-ALK-Rearrangement | Surgery | CR | 56; female; uterus; recurrence |
[200] | Crizotinib 280 mg/m2/day | CLTC-ALK rearrangement | – | CR | 8-months; male; common bile duct and celiac artery |
[201] | Alectinib 600 mg/day | SQSTM1-ALK rearrangement | Surgery | PR | 31; female; Recurrence of multifocal, unresectable multifocal disease |
[202] | Ceritinib 300 mg/m2/day | ALK rearrangement | Surgery, nonsteroidal anti-inflammatory drugs, chemotherapy with methotrexate and vinorelbine | CR | 17 years old; male; relapse with lung metastasis |
[203] | Alectinib | TNS1-ALK rearrangement | Surgery, 6 cycles of olaratumab (a PDGFR-alpha blocker) and doxorubicin | CR | 71; female; uterus; recurrence |
[31] | Alectinib 600 mg/day | SQSTM1-ALK rearrangement | – | PR | 46; male; unresectable recurrence |
[204] | Ensartinib 225 mg/day | RANBP2-ALK rearrangement | – | PR | 31male; metastatic recurrence |
[205] | Alectinib 600 mg/day | EML4-ALK rearrangement | – | PR | 26; male; left forearm; metastatic |
[206] | Alectinib 600 mg/day | EML4-ALK rearrangement | Surgery | PR | 55; male; metastatic |
[207] | Crizotinib Ceritinib to 600 mg daily | TPM3-ALK rearrangement | Surgery, celecoxib | PR | 32; male; left lung and chest wall, medial right thigh, right gluteal muscle, and omentum |
[208] | Crizotinib Ceritinib 750 mg/daily | ALK G1269A mutation | Surgery | PR | 36; female; lung; recurrence |
[209] | Crizotinib Ceritinib 750 mg/daily Alectinib 600 mg/daily Lorlatinib 100 mg/daily | ALK rearrangement | – | PR | 18; female; brain; metastatic |
[210] | Crizotinib Brigatinib 180 mg/daily Lorlatinib 180 mg/daily | Rearrangement of the TFG-ROS1 rearrangement | Surgery | CR | 14; female; brain; metastatic |
[211] | Crizotinib 250 mg/twice daily Alectinib 600 mg/twice daily Ceritinib 450 mg/daily Lorlatinib 100 mg/daily | PRRC2B-ALK rearrangement | Surgery | PR | 42; female; pelvis; recurrence |
[212] | Crizotinib 250 mg/twice daily Ceritinib 450 mg/daily Alectinib 600 mg/twice daily | RRBP1-ALK rearrangement | – | PR | 22; male; abdomen; metastatic |
Note: *In the studies referenced, the doses administered exhibited variability throughout the therapeutic course, mainly due to drug-related toxicities. We presented the initial or principal dose used among the patient cohort. CR-complete response, PR-partial response, SD-stable disease, ALK-anaplastic lymphoma kinase, RANBP2-ran binding protein 2, CLTC-clathrin heavy chain, RRBP1-ribosome-binding protein 1, PRRC2B-proline-rich coiled-coil 2B, DCTN1-dynactin subunit 1, EML4-echinoderm microtubule-associated protein-like 4, NUMA1-nuclear mitotic apparatus protein 1, LRRFIP1-leucine-rich repeat of flightless-1 interacting protein 1, IGFBP5-insulin-like growth factor-binding protein 5, SQSTM1-sequestosome 1, TNS1-tensin 1, TPM3-tropomyosin 3 TFG-tropomyosin-receptor kinase fused gene, ROS1-proto-oncogene 1 receptor tyrosine kinase, PDGFR-platelet-derived growth factor receptor, VAC/VA-vincristine, actinomycin-D, and cyclophosphamide.